Program
Albumin-Bound Paclitaxel
Also written as “ABI-007”, “nab-paclitaxel” and “Nab-paclitaxel”.
Its studies are mostly in Pancreatic Neoplasms · Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms · Melanoma, led by 11 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 380 open or running | phase 4since May 28, 2014 | Sep 30, 2002 | none ahead |
| CSPC Pharmaceutical Group | 31 open or running | phase 3since Aug 15, 2017 | Aug 15, 2017 | none ahead |
| Theriva Biologics SL | 20 open or running | phase 1since Jan 21, 2014 | Jan 21, 2014 | none ahead |
| academic-thoracic-oncology-medical-investigators-consortium | 10 open or running | phase 2since Mar 24, 2016 | Mar 24, 2016 | none ahead |
| Astellas Pharma | 10 open or running | phase 1since Nov 6, 2009 | Nov 6, 2009 | none ahead |
| ebg-medaustron-gmbh | 11 open or running | no phasesince May 10, 2021 | May 10, 2021 | Dec 31, 2026NCT04894643 |
| Lee's Pharmaceutical | 10 open or running | phase 1since Sep 8, 2020 | Sep 8, 2020 | none ahead |
| Novartis | 10 open or running | phase 2since Jul 1, 2008 | Jul 1, 2008 | none ahead |
| NovoCure | 10 open or running | phase 2since Feb 29, 2024 | Feb 29, 2024 | none ahead |
| Otsuka | 10 open or running | phase 2since Apr 16, 2008 | Apr 16, 2008 | none ahead |
| synergene-therapeutics-inc | 11 open or running | phase 2since Dec 18, 2014 | Dec 18, 2014 | Dec 2026phase 2 · NCT02340117 |
Also a collaborator on its studies: Gilead Sciences, Pfizer, Criterium and Shanghai Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 36 studies since Sep 30, 2002.
- Oct 1, 2014Phase 1 study in Pancreatic NeoplasmsBristol-Myers Squibb · NCT02267707 · 1 enrolled · United States, Germany
- Nov 10, 20142 phase 2 studiesBristol-Myers Squibb · NCT02289456, NCT02301143
- Dec 3, 2014Phase 1 study in Breast NeoplasmsBristol-Myers Squibb · NCT02309177 · 114 enrolled · United States
- Dec 18, 2014synergene-therapeutics-inc’s first study: phase 2 study in Pancreatic NeoplasmsNew to synergene-therapeutics-incsynergene-therapeutics-inc · NCT02340117 · 28 enrolled · United States
- Nov 30, 2015Phase 1 study in Pancreatic NeoplasmsBristol-Myers Squibb · NCT02620800 · 12 enrolled · United States
- Mar 24, 2016academic-thoracic-oncology-medical-investigators-consortium’s first study: phase 2 study in Pancreatic NeoplasmsNew to academic-thoracic-oncology-medical-investigators-consortiumacademic-thoracic-oncology-medical-investigators-consortium · NCT02723331 · 48 enrolled · United States
- Jun 9, 2017Phase 2 study in Colorectal NeoplasmsBristol-Myers Squibb · NCT03184870 · 332 enrolled · United States, Australia, Belgium and more
- Aug 15, 2017CSPC Pharmaceutical Group’s first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT03262948 · 388 enrolled
- Nov 6, 2017Phase 2 study in Advanced Pancreatic CancerBristol-Myers Squibb · NCT03336216 · 205 enrolled · United States, Canada, Denmark and more
- Sep 8, 2020Lee's Pharmaceutical’s first study: phase 1 study in Advanced Urothelial CarcinomaNew to Lee's PharmaceuticalLee's Pharmaceutical · NCT04603846 · 20 enrolled · China
- May 10, 2021ebg-medaustron-gmbh’s first study: no phase study in Pancreatic NeoplasmsNew to ebg-medaustron-gmbhebg-medaustron-gmbh · NCT04894643 · 10 planned · Austria
- Apr 12, 2022Phase 1 study in Advanced Solid TumorCSPC Pharmaceutical Group · NCT05344742 · 116 enrolled
- Feb 29, 2024NovoCure’s first study: phase 2 study in Pancreatic NeoplasmsNew to NovoCureNovoCure · NCT06390059 · 84 enrolled · Czechia, Germany, Spain and more
- Jul 24, 2025Phase 1 study in BioequivalenceCSPC Pharmaceutical Group · NCT07096869 · 28 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Pancreatic Neoplasmssynergene-therapeutics-inc · NCT02340117
- Dec 31, 2026Primary completion: no phase study in Pancreatic Neoplasmsebg-medaustron-gmbh · NCT04894643
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 51 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07096869Bioequivalence · China | 1 | Recruiting | CSPC Pharmaceutical Group | Dec 31, 2025 | 28 |
| NCT06390059Pancreatic Neoplasms · Czechia, Germany, Spain and more | 2 | Completed | NovoCure | Nov 18, 2025 | 84 |
| NCT05344742Advanced Solid Tumor | 1 | UNKNOWN | CSPC Pharmaceutical Group | Mar 2024 | 116 |
| NCT04894643Pancreatic Neoplasms · Austria | – | Recruiting | ebg-medaustron-gmbh | Dec 31, 2026 | 10 |
| NCT04603846Advanced Urothelial Carcinoma · China | 1 | UNKNOWN | Lee's Pharmaceutical | Oct 1, 2022 | 20 |
| NCT03336216Advanced Pancreatic Cancer · United States, Canada, Denmark and more | 2 | Completed | Bristol-Myers Squibb | Jun 1, 2023 | 205 |
| NCT03262948Carcinoma, Non-Small-Cell Lung | 3 | UNKNOWN | CSPC Pharmaceutical Group | Oct 1, 2019 | 388 |
| NCT03184870Colorectal Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Bristol-Myers Squibb | Apr 6, 2023 | 332 |
| NCT02723331Pancreatic Neoplasms · United States | 2 | Completed | academic-thoracic-oncology-medical-investigators-consortium | Dec 8, 2022 | 48 |
| NCT02620800Pancreatic Neoplasms · United States | 1 | Completed | Bristol-Myers Squibb | Oct 29, 2018 | 12 |
| NCT02340117Pancreatic Neoplasms · United States | 2 | Active, not recruiting | synergene-therapeutics-inc | Dec 2026 | 28 |
| NCT02309177Breast Neoplasms · United States | 1 | Completed | Bristol-Myers Squibb | Sep 12, 2018 | 114 |
| NCT02301143Pancreatic Neoplasms · United States, Canada, France and more | 2 | Completed | Bristol-Myers Squibb | Nov 21, 2017 | 107 |
| NCT02289456Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Bristol-Myers Squibb | Feb 22, 2017 | 40 |
| NCT02267707Pancreatic Neoplasms · United States, Germany | 1 | Terminated | Bristol-Myers Squibb | Feb 10, 2016 | 1 |
| NCT02250326Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more | 2 | Completed | Bristol-Myers Squibb | Jul 17, 2017 | 240 |
| NCT02151149Carcinoma, Non-Small-Cell Lung · United States | 4 | Completed | Bristol-Myers Squibb | Jul 14, 2017 | 143 |
| NCT02103062Colorectal Neoplasms · France | 2 | Completed | Bristol-Myers Squibb | Nov 10, 2014 | 41 |
| NCT02045602Neoplasms · Spain | 1 | Completed | Theriva Biologics SL | May 2019 | 42 |
| NCT02045589Neoplasms · Spain | 1 | Completed | Theriva Biologics SL | Oct 2016 | 8 |
| NCT02027428Carcinoma, Squamous Cell · United States, Germany, Italy and more | 3 | Completed | Bristol-Myers Squibb | Sep 15, 2017 | 427 |
| NCT02017015Pancreatic Neoplasms · China | 2 | Completed | Bristol-Myers Squibb | Jun 1, 2015 | 83 |
| NCT01964430Pancreatic Neoplasms · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Jun 30, 2022 | 866 |
| NCT01962103Neuroblastoma · United States, Canada, France and more | 2 | Completed | Bristol-Myers Squibb | Dec 5, 2017 | 107 |
| NCT01933061Melanoma | 2 | Withdrawn | Bristol-Myers Squibb | Jan 2014 | 0 |
| NCT01881230Breast Neoplasms · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Oct 28, 2016 | 191 |
| NCT01010945Adenocarcinoma · United States | 1 | Completed | Astellas Pharma | Jan 25, 2012 | 19 |
| NCT00864253Melanoma · United States, Australia, Canada and more | 3 | Completed | Bristol-Myers Squibb | Jun 1, 2012 | 529 |
| NCT00844649Pancreatic Neoplasms · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | Sep 17, 2012 | 861 |
| NCT00709761Breast Neoplasms · United States | 2 | Completed | Novartis | Jan 5, 2011 | 60 |
| NCT00661167Stomach Neoplasms · Japan | 2 | Completed | Otsuka | May 2011 | 56 |
| NCT00540514Carcinoma, Non-Small-Cell Lung · United States, Canada | 3 | Completed | Bristol-Myers Squibb | Oct 1, 2009 | 1,052 |
| NCT00518284Peripheral Vascular Diseases · United States | 2 | Terminated | Bristol-Myers Squibb | Aug 2009 | 6 |
| NCT00456846Breast Neoplasms · Canada | 2 | Terminated | Bristol-Myers Squibb | Dec 11, 2012 | 123 |
| NCT00407407Fallopian Tube Neoplasms · United States | 1 | Terminated | Bristol-Myers Squibb | Feb 1, 2008 | 6 |
| NCT00398086Pancreatic Neoplasms · United States | 2 | Completed | Bristol-Myers Squibb | Sep 1, 2008 | 67 |
| NCT00394251Breast Neoplasms · United States | 2 | Completed | Bristol-Myers Squibb | Mar 1, 2007 | 197 |
| NCT00394082Breast Neoplasms · United States | 2 | Completed | Bristol-Myers Squibb | Sep 1, 2009 | 50 |
| NCT00281528Breast Neoplasms · United States, Puerto Rico | 2 | Terminated | Bristol-Myers Squibb | Jul 1, 2010 | 208 |
| NCT00274456Breast Neoplasms · Ukraine | 2 | Completed | Bristol-Myers Squibb | Mar 1, 2008 | 302 |
| NCT00274443Carcinoma, Non-Small-Cell Lung · Russian Federation | 2 | Completed | Bristol-Myers Squibb | Jun 1, 2007 | 250 |
| NCT00249002Hemodialysis Graft Dysfunction · United States | 2 | Terminated | Bristol-Myers Squibb | Nov 1, 2007 | 9 |
| NCT00140140Neoplasm Metastasis · United States | 2 | Terminated | Bristol-Myers Squibb | Feb 2008 | 16 |
| NCT00124943Coronary Restenosis | 2 | Completed | Bristol-Myers Squibb | Aug 2009 | 112 |
| NCT00107094Breast Neoplasms · United States | 1 | Completed | Bristol-Myers Squibb | 30 | |
| NCT00093145Breast Neoplasms · United States | 2 | Completed | Bristol-Myers Squibb | Oct 1, 2008 | 32 |
| NCT00093119Melanoma · United States | 2 | Completed | Bristol-Myers Squibb | Feb 2005 | 75 |
| NCT00073723Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Bristol-Myers Squibb | 75 | |
| NCT00046527Breast Neoplasms · United States | 3 | Completed | Bristol-Myers Squibb | 460 | |
| NCT00046514Breast Neoplasms · United States | 2 | Completed | Bristol-Myers Squibb | 100 | |
| NCT00046423Neoplasms · United States | 1 | Completed | Bristol-Myers Squibb | 20 |
How it is read
Names in the registry
- “ABI-007”, 15 entries
- “nab-paclitaxel”, 13 entries
- “Nab-paclitaxel”, 12 entries
- “Nab-Paclitaxel”, 9 entries
- “nab-Paclitaxel”, 6 entries
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 24 studies
- Breast Neoplasms, 14 studies
- Carcinoma, Non-Small-Cell Lung, 11 studies
- Triple Negative Breast Neoplasms, 4 studies
- Melanoma, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.